A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy
Advanced or Metastatic Solid Tumors|Non-Small Cell Lung Cancer
DRUG: NC318|DRUG: Pemetrexed/Carboplatin|DRUG: Nab paclitaxel/Carboplatin|DRUG: Docetaxel
Number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0, Frequency, duration, and severity of treatment-emergent adverse events (AEs), 14 months
Objective Response Rate per RECIST, Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1, 14 months|Duration of Response per RECIST, Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1, 14 months|Disease Control Rate per RECIST, Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1, 14 months|Progression-Free Survival per RECIST, Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1, 14 months|Overall Survival per RECIST, Overall Survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and modified RECIST (mRECIST) v1.1, 14 months|Maximum Plasma Concentration (Cmax) of NC318, To evaluate the Maximum Plasma Concentration (Cmax) of NC410, 14 months
This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy